Lyell Immunopharma (NASDAQ:LYEL) Trading 3.5% Higher - What's Next?

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report)'s share price traded up 3.5% during trading on Monday . The company traded as high as $9.03 and last traded at $8.99. 110,285 shares changed hands during mid-day trading, an increase of 59% from the average session volume of 69,486 shares. The stock had previously closed at $8.69.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HC Wainwright restated a "neutral" rating and issued a $20.00 price target on shares of Lyell Immunopharma in a report on Wednesday, April 16th. Wall Street Zen upgraded Lyell Immunopharma to a "hold" rating in a report on Friday, June 6th.

Lyell Immunopharma Stock Up 3.5%

The firm has a market cap of $133.14 million, a P/E ratio of -0.36 and a beta of -0.26. The firm has a fifty day moving average of $9.10 and a 200-day moving average of $11.15.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.80) by $0.20. Lyell Immunopharma had a negative return on equity of 73.66% and a negative net margin of 514,649.22%. The business had revenue of $0.01 million for the quarter. On average, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Institutional Trading of Lyell Immunopharma

Several institutional investors and hedge funds have recently bought and sold shares of LYEL. Decheng Capital LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth about $7,622,000. Foresite Capital Management V LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth about $5,205,000. venBio Partners LLC acquired a new position in Lyell Immunopharma during the fourth quarter worth approximately $4,545,000. Almitas Capital LLC increased its position in Lyell Immunopharma by 136.3% during the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Lyell Immunopharma by 716.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company's stock worth $1,032,000 after buying an additional 1,414,746 shares during the last quarter. Institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.